Dublin, March 23, 2023 (GLOBE NEWSWIRE) -- The "Macular Degeneration Treatment Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
This report provides strategists, marketers and senior management with the critical information they need to assess the market.
The global macular degeneration treatment market grew from $8.44 billion in 2022 to $9.43 billion in 2023 at a compound annual growth rate (CAGR) of 11.7%. The macular degeneration treatment market is expected to grow to $14.3 billion in 2027 at a CAGR of 11.0%.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Major players in the macular degeneration treatment market are Novartis AG, Bausch Health Companies Inc., Regenxbio Inc., F Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., GlaxoSmithKline plc, Bayer AG, Neurotech Pharmaceuticals Inc., Ophthotech Corporation, StemCells Inc., Pfizer Inc., Santen Pharmaceuticals, Alimera Sciences Inc., Aerie Pharmaceutical Inc., Panoptica, Allergan Inc., Valeant Pharmaceuticals, and Rxi Pharmaceuticals Inc.
The macular degeneration treatment market includes revenues earned by entities by anti-angiogenic drugs, photodynamic therapy, laser therapy and low vision aids. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
Macula refers to the central portion of the retina, a light-sensitive layer of tissue at the back of the eye. The macula is responsible for central vision. Degeneration of the macula, which affects the central part of the retina (the macula) and results in distortion or loss of central vision, occurs most commonly after the age of 60 and is referred to as age-related macular generation (AMD). The macular degeneration treatment is used to treat macular degeneration eye disease and slow the disease and prevent severe loss of vision.
In 2022, North America will be the largest region in the macular degeneration treatment market. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
The main disease stages in the macular degeneration treatment market are early-stage AMD, intermediate AMD, and late-stage AMD. In early-stage AMD, the macula changes, with medium-sized drusen deposits and no pigment changes, but this does not impact vision. Intermediate AMD is when vision may get blurry or wavy with large drusen or pigment changes. In late-stage AMD, the central vision fails completely, causing vision loss.
The different types of macular degeneration treatments include wet macular degeneration and dry macular degeneration. The different routes of administration of macular degeneration treatment include oral, injectable, and others used by different end-users such as ambulatory surgical centers, ophthalmic clinics, and hospitals.
The increasing burden of retinal disorders is expected to propel the growth of the macular degeneration treatment market. Retinal disorders affect the vital tissue and affect the way individuals process visual information, leading to distorted or absent vision.
According to a study done in Tanzania in 2020 about the prevalence of retinal diseases and associated risk factors, out of 1,007 people, the prevalence of vitreoretinal disorders was 22.8% (230/1,007). The study was conducted by OSLI Retina, which focuses solely on retinal diseases, surgery, and pharmacotherapy. The leading retinal diseases were age-related hypertensive macular scars (2.7%), retinopathy (4.5%), and degeneration (7.0%).
According to the American Academy of Opthalmology, in 2050, an estimated 7.32 million people in the United States will have primary open-angle glaucoma, with the highest numbers among populations aged 70 to 79 years (32%), women (50%), and Hispanics (50%). The largest demographic group is Hispanic men. Therefore, the increasing burden of retinal disorders is driving the growth of the macular degeneration treatment market.
The development of advanced therapies is a key trend gaining popularity in the macular degeneration treatment market. Advanced therapy, including gene therapy, for the treatment of disease has seen development in recent years, particularly in the world of inherited retinal disease.
For instance, in October 2021, Genentech, a US-based biotechnology company, announced that FDA has approved Susvimo, a new treatment for wet age-related macular degeneration. Susvimo is the first wet AMD treatment to offer an alternative to the standard-of-care eye injections required as frequently as once per month in the last 15 years. Susvimo will help people with wet AMD retain their vision with as few as two treatments per year by continually injecting medication into the eye via a refillable implant.
In September 2021, Novartis, a Swiss-based pharmaceutical company, acquired Arctos Medical for an undisclosed amount. The acquisition is expected to allow Novartis to find treatments for patients with vision loss and leverage the potential of optogenetics as the basis of successful therapeutics. Arctos Medical is a Switzerland-based developer of smart medical devices and gene therapy approaches for ophthalmological diseases for treating blindness.
The countries covered in the Macular Degeneration Treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2023 - 2027 |
| Estimated Market Value (USD) in 2023 | $9.43 billion |
| Forecasted Market Value (USD) by 2027 | $14.3 billion |
| Compound Annual Growth Rate | 11.0% |
| Regions Covered | Global |
Key Topics Covered:
1. Executive Summary
2. Macular Degeneration Treatment Market Characteristics
3. Macular Degeneration Treatment Market Trends And Strategies
4. Macular Degeneration Treatment Market - Macro Economic Scenario
4.1 COVID-19 Impact On Macular Degeneration Treatment Market
4.2 Ukraine-Russia War Impact On Macular Degeneration Treatment Market
4.3 Impact Of High Inflation On Macular Degeneration Treatment Market
5. Macular Degeneration Treatment Market Size And Growth
5.1. Global Macular Degeneration Treatment Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Macular Degeneration Treatment Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Macular Degeneration Treatment Market Segmentation
6.1. Global Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Wet Macular Degeneration
- Dry Macular Degeneration
6.2. Global Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Early-Stage AMD
- Intermediate AMD
- Late-Stage AMD
6.3. Global Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Oral
- Injectable
- Other Route of Administration
6.4. Global Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Ambulatory Surgical Centers
- Ophthalmic Clinics
- Hospitals
7. Macular Degeneration Treatment Market Regional And Country Analysis
7.1. Global Macular Degeneration Treatment Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Macular Degeneration Treatment Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/ngn3el
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
